Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Synergy Asset Management LLC

Synergy Asset Management LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 44.5% during the 1st quarter, HoldingsChannel.com reports. The fund owned 106,500 shares of the biopharmaceutical company’s stock after selling 85,305 shares during the period. Gilead Sciences makes up 1.5% of Synergy Asset Management LLC’s portfolio, making the stock its 19th largest position. Synergy Asset Management LLC’s holdings in Gilead Sciences were worth $11,933,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC increased its stake in shares of Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 2,450 shares during the period. Venturi Wealth Management LLC increased its position in Gilead Sciences by 78.0% during the 4th quarter. Venturi Wealth Management LLC now owns 2,658 shares of the biopharmaceutical company’s stock worth $246,000 after purchasing an additional 1,165 shares during the period. Global Retirement Partners LLC increased its position in Gilead Sciences by 2.2% during the 4th quarter. Global Retirement Partners LLC now owns 8,982 shares of the biopharmaceutical company’s stock worth $830,000 after purchasing an additional 194 shares during the period. Bell Bank grew its holdings in Gilead Sciences by 4.9% during the fourth quarter. Bell Bank now owns 118,187 shares of the biopharmaceutical company’s stock worth $10,917,000 after acquiring an additional 5,546 shares during the period. Finally, Oxbow Advisors LLC grew its holdings in Gilead Sciences by 0.6% during the fourth quarter. Oxbow Advisors LLC now owns 71,941 shares of the biopharmaceutical company’s stock worth $6,645,000 after acquiring an additional 450 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, March 27th. Oppenheimer lowered their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, April 25th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Wells Fargo & Company upped their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Finally, Cantor Fitzgerald started coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 price target on the stock. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $110.55.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $99.82, for a total value of $249,550.00. Following the transaction, the chief financial officer now owns 165,674 shares in the company, valued at $16,537,578.68. This trade represents a 1.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the transaction, the insider now owns 121,152 shares in the company, valued at $13,026,263.04. The trade was a 18.77% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 48,500 shares of company stock worth $5,236,245 over the last quarter. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Stock Up 0.5%

GILD opened at $108.50 on Friday. Gilead Sciences, Inc. has a 52 week low of $66.01 and a 52 week high of $119.96. The firm has a market cap of $134.97 billion, a P/E ratio of 22.84, a PEG ratio of 0.70 and a beta of 0.29. The business’s fifty day simple moving average is $106.16 and its 200 day simple moving average is $102.81. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The company had revenue of $6.67 billion for the quarter, compared to analysts’ expectations of $6.77 billion. During the same period last year, the company earned ($1.32) EPS. The firm’s revenue for the quarter was down .3% compared to the same quarter last year. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.91%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.